{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.9","upperLimit":"26.1","value":"15.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Complete and Partial Tumor Response by (Response Evaluation Criteria in Solid Tumors) RECIST 1.0","dispersionType":"90% Confidence Interval","groups":[{"description":"AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)","id":"OG000","title":"AZD6244"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Every other cycle","title":"Tumor Response","type":"PRIMARY","unitOfMeasure":"percentage of patients"}